Ixekizumab Shows Promise Treating Psoriatic Arthritis

In a pivotal phase 3 clinical trial, patients with psoriatic arthritis (PsA) who did not gain long-lasting benefit from standard of care treatments experienced a reduction in symptoms, including joint tenderness and swelling, after receiving treatment with ixekizumab (Taltz).
Ixekizumab is an injectable monoclonal antibody designed to block interleukin-17 (IL-17). It received FDA approval in March 2016 to treat adults with moderate to severe plaque psoriasis.
The randomized, double-blind, placebo-controlled SPIRIT-P2 trial was conducted at 109 centers in 10 countries. Included in the study were 314 adults with PsA, for whom available biological drugs lost their efficacy or were unsuccessful to begin with.
For a 24-week period, 109 patients received regular injections of ixekizumab every 2 weeks, 94 received a placebo every 2 weeks, and 111 alternated every 2 weeks between receiving injections of ixekizumab and placebo.
The results of the study, published in The Lancet, showed that more than 50% of patients in the ixekizumab arm experienced at least a 20% reduction in the number of tender and swollen joints. Ixekizumab significantly outperformed the placebo arm, according to the authors.
Psoriatic arthritis is an inflammatory autoimmune disease that causes stiffness, pain, and swelling of joints. The disease typically emerges between the ages of 30 and 50 years.
Three of the top 10 selling drugs in the United States––in dollar sales––are biologics to treat psoriatic arthritis and the more common rheumatoid arthritis. Adalimumab, etanercept, and infliximab are designed to block the tumor necrosis factor (TNF), which stimulates the immune response and inflammation.
Despite this, TNF inibitor medications are not as successful in patients with psoriatic arthritis.
“Only about half of psoriatic arthritis patients who are given TNF inhibitors get better,” said senior author Mark Genovese, MD.
Although the cause of the disease remains unknown, researchers believe ixekizumab has potential.   
In an earlier phase 3 trial, ixekizumab demonstrated efficacy for patients with PsA who had not received prior treatment with TNF inhibitors.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Tildrakizumab (Ilumetri) received approval by the European Commission for the treatment of moderate-to-severe chronic plaque psoriasis.
The FDA has accepted for review Regeneron Pharmaceuticals’ supplemental Biologics License Application (sBLA) of aflibercept (EYLEA Injection) to treat diabetic retinopathy.
Tocilizumab’s newest formulation offers an additional administration option for children diagnosed systemic juvenile idiopathic arthritis, a rare and debilitating disease.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.